# Diabetes Research Hub — Monitor Report

**Run date:** 2026-05-04
**Run type:** Automated scheduled review (no user present)
**Hub root:** `C:\Users\justi\OneDrive\Diabetes_Research`
**Comparison window:** 2026-04-27 → 2026-05-04 (7 days)

---

## File System Status

| File | Last Modified | Status |
|------|---------------|--------|
| Analysis/Results/hub_monitor_report.md | 2026-05-04 07:05 | Fresh |
| Analysis/Results/clinical_trials_latest.json | 2026-05-04 07:04 | Fresh |
| Analysis/Results/pubmed_recent_latest.json | 2026-05-04 07:05 | Fresh |
| Analysis/Results/literature_gap_report.md | 2026-05-03 14:07 | Fresh |
| Analysis/Results/literature_gap_data.json | 2026-04-20 15:35 | **STALE — 14 days old** |
| Analysis/Results/agent_state.json | 2026-05-03 08:11 | Fresh |
| Diabetes_Research_Tracker.xlsx | 2026-04-17 14:50 | Aging — 17 days |

Hub-monitor flagged 557 result files older than 14 days; most are dated daily snapshots, expected. The single actionable item is `literature_gap_data.json`, which is exactly 14 days old. Re-running the gap analysis is recommended this week to keep BRONZE-validated findings current.

Daily snapshot pipelines (clinical_trials and pubmed_recent) ran successfully today. The hub_monitor.py scan reports 7 new files, 30 modified, 0 removed, 752 unchanged.

---

## Clinical Trial Changes

**Snapshot summary** (2026-05-04 vs 2026-04-27):
- 778 total trials tracked across 5 categories
- 9 new trials added; 2 trials dropped from feed
- 4 status changes
- 0 newly posted results in the 7-day window (per snapshot diff)
- 261 RECRUITING, 270 COMPLETED, 130 NOT_YET_RECRUITING

**Status changes (last 7 days):**

| NCT ID | Previous | Current | Trial |
|--------|----------|---------|-------|
| NCT07355270 | NOT_YET_RECRUITING | RECRUITING | RadioFrequency Vapor Ablation pilot (T2D) |
| NCT07321678 | RECRUITING | ACTIVE_NOT_RECRUITING | ASC30 Tablets — Phase 2/3 |
| NCT07400588 | RECRUITING | ACTIVE_NOT_RECRUITING | Aleniglipron Phase 2 in T2D |
| NCT07422831 | NOT_YET_RECRUITING | ENROLLING_BY_INVITATION | T2D Intermittent Sensors |

**Key Phase 3 RECRUITING trials worth tracking** (43 total in this state):

| NCT ID | Sponsor | Therapy | Indication |
|--------|---------|---------|------------|
| NCT04786262 | Vertex | VX-880 (zimislecel) | T1D islet cell therapy |
| NCT06832410 | Vertex | VX-880 (zimislecel) | T1D islet cell therapy (2nd Phase 3) |
| NCT07076199 | Novo Nordisk | Insulin Icodec | T2D weekly basal insulin |
| NCT07222137 | Eli Lilly | Baricitinib | Delay Stage 3 T1D |
| NCT07222332 | Eli Lilly | Baricitinib | Preserve beta-cell function in children |
| NCT06217302 | Doria/Joslin | Sotagliflozin | T1D kidney function decline |
| NCT05819138 | U Colorado | Semaglutide | T1D cardiovascular outcomes |

**Recently posted results (since 2026-04, snapshot lookback):**
- **NCT05971940** — Orforglipron (LY3502970) Phase 3 in T2D — Eli Lilly (results 2026-04-22) — directly relevant to FDA Foundayo approval (see Breaking News)
- **NCT05649137** — Semaglutide Phase 3 in excess weight (results 2026-04-27) — Novo Nordisk
- **NCT05144984** — Semaglutide + Cagrilintide combination Phase 2 (results 2026-04-09) — Novo Nordisk
- **NCT01633177** — Vitamin D + Omega-3 for diabetes prevention Phase 3 (results 2026-04-03)
- **NCT05727579** — Ertugliflozin + sodium intake Phase 4

Note: snapshot diff vs. last week shows 0 *new* postings in that window because most of these were posted earlier in April and were already in the prior snapshot.

---

## PubMed Highlights

**Volume:** 139 unique papers retrieved across 16 alert domains (30-day lookback). 99 papers are new vs. the 2026-04-27 snapshot.

**Domain activity (PubMed total counts):**
- High activity: Diabetes AI/ML (165), Diabetes Biomarker (131), T2D GLP-1 New (117), Diabetes Microbiome (114)
- Low activity: GLP-1 Pharmacogenomics (1), LADA New Research (2), Diabetes Drug Repurposing (4)

The continued sparse output in **GLP-1 Pharmacogenomics**, **LADA**, and **Drug Repurposing** aligns with three of the high-priority gaps in our literature_gap_data.json analysis — these remain genuine opportunities, not just artifacts of search terms.

**Cross-domain new papers** (highest-value signals — 14 in this 7-day window):

| PMID | Domains | Title | Journal |
|------|---------|-------|---------|
| 42056522 | T2D GLP-1 New, GLP-1 Pharmacogenomics | GLP-1R–GIPR–PPARα/γ/δ quintuple agonism corrects obesity and diabetes in mice | **Nature** |
| 42051156 | T1D Immunotherapy, Key Therapy: teplizumab | Considerations for clinical use of teplizumab in stage 2 T1D — Consensus | Diabetic Medicine |
| 42023429 | T1D Immunotherapy, Diabetes Gene Therapy | Gene Therapy and Gene Editing in T1D: CRISPR-based β-cell replacement and Tregs | Diabetes, Obesity & Metabolism |
| 42069247 | Diabetes AI/ML, Diabetes Biomarker | ML-enhanced plasma proteomics discriminates pancreatic cancer-associated diabetes | J Proteomics |
| 42066985 | Diabetes AI/ML, Diabetes Multi-Omics | Integrated plasma proteomics + metabolomics for immunometabolic prediction | Metabolism |
| 42061668 | Diabetes Microbiome, Diabetes Multi-Omics | Low-carbohydrate diet in autoimmune diseases — review | Autoimmunity Reviews |
| 42062589 | Diabetes Microbiome, Diabetes Health Equity | GDM → T2D risk: gut microbiome role | Diabetologia |
| 42070230 | Diabetes Gene Therapy, Diabetes Multi-Omics | DES-AAV-Foxo1 delivery for diabetic corneal disease | Advanced Science |
| 42034968 | T1D Stem Cell Cure, T1D Immunotherapy | Bone marrow–derived cells for autoimmune T1D | BMC Immunology |
| 42046753 | T1D Immunotherapy, Closed Loop AP | Active sitting breaks on glucose & vascular outcomes | BMJ Open Sport Exerc Med |

**Key-therapy mentions in last 7 days:**
- **Teplizumab:** 3 new papers (PMIDs 41535597, 41796109, 42051156) — driven by April 22 FDA pediatric approval
- **Orforglipron:** 3 papers
- **Retatrutide:** 2 papers
- **Baricitinib:** 2 papers
- **Icodec:** 3 papers
- **Dapagliflozin:** 5 papers (24 in PubMed total — generic approval news)
- **Zimislecel:** 0 new in 7-day snapshot, but Vertex presented positive Phase 1/2 ADA data + NEJM publication this period (see Breaking News)
- **CagriSema:** 0 keyword hits, but NCT05144984 results were just posted

**High-impact venue papers (new):** Nature (42056522), Lancet (42061392 — AI in medicine), Nature Genetics (42067644), Nature Communications (42069741), JAMA Dermatology (42054048 — GLP-1 in psoriasis).

---

## Gap Analysis Summary

Source: `literature_gap_data.json` (generated 2026-04-20 — **14 days old, refresh recommended**).

**Top 5 under-researched intersections (gap_score = 100, by joint publications):**

| Rank | Domain 1 | Domain 2 | Joint Pubs | Tier 1 alignment |
|------|----------|----------|------------|------------------|
| 1 | Beta Cell Regen | Health Equity | 0 | Yes — Tier 1 #6 (Epidemiological/equity analysis) |
| 2 | Insulin Resistance | Islet Transplant | 1 | Yes — Tier 1 #2 (Literature synthesis) and #3 (Trial intelligence) |
| 3 | Islet Transplant | Drug Repurposing | 0 | **Strong** — Tier 1 #4 (Drug Repurposing) directly applies |
| 4 | Islet Transplant | Health Equity | 0 | Yes — Tier 1 #6 |
| 5 | Gene Therapy | LADA | 0 | Yes — Tier 1 #2 (cross-domain synthesis) |

The Insulin Resistance × Islet Transplant gap (#2) is interesting: there's exactly 1 joint publication despite 18,889 IR papers and 242 islet transplant papers. Worth a targeted PubMed dive — IR in transplant recipients affects graft survival but appears nearly invisible in the literature.

The Islet Transplant × Drug Repurposing gap (#3) maps directly onto our Tier 1 Drug Repurposing project — this is exactly the kind of computational opportunity our pipeline is designed for.

---

## Breaking News (web check — last 30 days, only significant items)

1. **FDA approved Tzield (teplizumab-mzwv) for ages 1+ to delay Stage 3 T1D** — April 22, 2026 (Sanofi). Supplemental BLA based on PETITE-T1D Phase 4. Major expansion from prior age 8+ indication. **Action implied:** Update tracker; align with NCT06951074 / NCT07548996 immunotherapy lineage; relevant to gap analysis on T1D immunotherapy.
2. **FDA approved Foundayo (orforglipron) — first oral GLP-1 pill (no food/water restrictions)** — April 1, 2026 (Eli Lilly). Lines up with NCT05971940 results posted April 22. **Action implied:** This is a category-establishing approval; recheck Drug Repurposing screen for oral-GLP-1 followers.
3. **FDA approved first generic dapagliflozin** — April 7, 2026. Affects T2D affordability landscape. Relevant to Drug Repurposing × Health Equity gap.
4. **Vertex zimislecel (VX-880) Phase 1/2 NEJM publication** — April 2026. 12/12 patients restored endogenous insulin secretion; 10/12 insulin-independent; severe hypoglycemia events ceased. Phase 3 (FORWARD) on track for global regulatory submissions. Status of NCT04786262 / NCT06832410 in our tracker is consistent (RECRUITING).
5. **MannKind Afrezza pediatric (ages 4–17) FDA decision expected May 29, 2026.** Worth re-checking on that date.

No items rise to the level of "rerun every analysis"; all five fit our existing tracking.

---

## Recommended Actions

In priority order:

1. **Re-run gap analysis** — `python project1_literature_gap_analysis.py`. The data file is 14 days old; refresh keeps gap rankings synced with the latest April PubMed indexing.
2. **Update Diabetes_Research_Tracker.xlsx** with:
   - Tzield pediatric approval (April 22) — T1D Immunotherapy row
   - Foundayo (orforglipron) approval (April 1) — T2D GLP-1 row
   - Dapagliflozin generic approval (April 7) — SGLT2 / Health Equity row
   - Vertex zimislecel NEJM publication — T1D Cell Therapy row
3. **Drug Repurposing × Islet Transplant deep-dive (Tier 1):** the gap analysis flags this as a top-3 opportunity with 0 joint papers and direct alignment with our Tier 1 #4 capability. Candidate next computational project.
4. **Cross-domain paper review** — three highest-priority new papers worth reading:
   - PMID 42056522 (Nature, GLP-1 quintuple agonism) — relevant to GLP-1 Pharmacogenomics × T2D GLP-1 gap
   - PMID 42023429 (DOM, CRISPR β-cell + Tregs) — direct Tier 1 cross-cut (Gene Therapy × Immunotherapy)
   - PMID 42051156 (Diabetic Medicine, teplizumab consensus) — pairs with FDA pediatric approval
5. **Status-change watch:** NCT07321678 (ASC30) and NCT07400588 (Aleniglipron) both moved RECRUITING → ACTIVE_NOT_RECRUITING this week — readout windows coming. Add to "Phase 2 readouts to monitor" list.
6. **Tracker file note:** `Diabetes_Research_Tracker.xlsx` last touched 2026-04-17. Consider a refresh after this monitor run is reviewed.

**Evidence levels (per Research Doctrine):** All gap rankings and cross-domain flagging in this report are BRONZE (single analytical source — PubMed keyword search via E-utilities). Drug-approval items from FDA / Sanofi / Lilly press releases are GOLD-equivalent (regulatory record). Phase 3 trial results from ClinicalTrials.gov are SILVER pending peer-reviewed publication.

---

*Generated by automated diabetes-hub-monitor scheduled task — 2026-05-04. No files were modified during this run.*
